Denmark-based biotech company Bavarian Nordic announced Thursday that the upcoming Phase III trial for ABNCoV2, its COVID-19 booster candidate, has been redesigned to compete against Pfizer-BioNTech's mRNA-based vaccine.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,